Pleasanton, California, U.S., October 7, 2026
Veeva Systems announced that more than 175 emerging biotechnology companies are using Veeva Basics to establish scalable technology foundations for drug development and commercialization. The pre-configured and pre-validated applications are designed to help emerging biotechs implement critical technology systems within weeks while reducing the time, effort and cost associated with traditional software deployment. Veeva Basics provides connected applications across clinical, regulatory, quality, medical and commercial operations, giving growing life sciences companies access to technology designed around their evolving needs. Built on the Veeva Vault Platform, the applications can scale as companies progress from early-stage development toward commercialization, helping emerging biotechs modernize operations while maintaining visibility and compliance throughout the drug development lifecycle.
Veeva Basics Helps Emerging Biotechs Modernize Operations
Emerging biotechnology companies are increasingly using Veeva Basics to replace manual and paper-based processes with digital life sciences applications that can be deployed quickly. According to Veeva, the pre-configured approach allows smaller companies to establish technology infrastructure without requiring large internal IT teams or extensive customization. Whitehawk Therapeutics, for example, is using Veeva Basics as it develops antibody-drug conjugates (ADCs) targeting difficult-to-treat cancers. The company said its partnership with Veeva helped replace paper processes with technology supporting regulatory and quality operations. The approach is particularly relevant for emerging biotechs operating with limited resources, where implementing scalable systems early can help establish more consistent processes as research programs advance. Veeva Basics is designed to provide a technology foundation that can evolve alongside companies as their operational requirements become more complex.
Regulatory Publishing Moves Toward Greater Control
One notable application is Veeva Submissions Publishing Basics, which enables biotechnology companies to bring regulatory publishing activities in-house rather than relying entirely on outsourced services. The application supports submission building and interactions with health authorities, providing regulatory teams with greater visibility and control across the regulatory lifecycle. For emerging biotechs preparing their first submissions to the U.S. Food and Drug Administration, establishing an internal regulatory publishing capability can help teams manage important regulatory milestones more efficiently. Structure Therapeutics reported that insourcing submission publishing through Veeva Basics provided stronger quality control and faster regulatory timelines. The company also highlighted the value of having modern applications with global support while retaining the flexibility to scale technology infrastructure as its business develops. These capabilities demonstrate how digital regulatory technology can support biotech companies as they move from research and development toward increasingly complex regulatory activities.
Advertisement
Veeva Builds Scalable Technology for Drug Development
Veeva says the growing adoption of Veeva Basics reflects the need for fast, scalable and industry-specific technology among emerging biotechs. The applications are built on the Veeva Vault Platform, allowing companies to establish a unified technology environment that can expand as they progress through different stages of drug development. By connecting capabilities across clinical, regulatory, quality, medical and commercial functions, Veeva Basics is positioned to help companies reduce technology complexity while supporting operational growth. More than 175 emerging biotechs are now establishing their technology foundation with the platform, according to Veeva. The company views these organizations as an important source of innovation across the life sciences industry and is developing Veeva Basics to match the pace at which emerging companies operate. Digital transformation, regulatory efficiency and scalable cloud technology are increasingly important as biotechnology companies advance innovative therapies toward clinical development and commercialization. Through Veeva Basics, Veeva is expanding access to pre-configured applications intended to help emerging biotechs accelerate operations and build technology infrastructure that can support their long-term drug development journey.
Source: Veeva Systems press release
